Clinical Efficacy of Dexlansoprazole vs Esomeprazole in Gastro-Oesophageal Reflux Disease: A Randomized Clinical Trial.
DOI:
https://doi.org/10.52206/jsmc.2022.12.3.699Abstract
Background: Gastro-Esophageal reflux disease (GERD) is a very common problem in a gastrointestinal clinical setting. Still, the best treatment for it remains debatable as there are many new drugs that have evolved for its treatment in addition to dietary modification.
Objective: To compare the clinical efficacy of Dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) for the resolution of symptoms of GERD.
Material and Methods: This randomized controlled trial or intervention was conducted for comparing the clinical efficacy of Dexlansoprazolevs Esomeprazole for the symptomatic treatment of GERD.A total of 100 endoscopically diagnosed patients were selected and were randomly allocated to two groups each containing 50 patients. Group 'A' contained 50 patients who were given 60 mg Dexlansoprazole for 2 weeks and group 'B' also contained the same number of patients receiving the treatment with Esomeprazole 40 mg for the same duration.After informed consent, a validated tool FSSG (Frequency Scale for the Symptoms of GERD) was used to collect the responses of patients. The Chi-square test was used to compare the responses of two groups considering a P-value of <0.05 as significant.
Results: Among domains of frequency scale for the symptoms of GERD, only dysphagia was significantly better in Dexlansoprazole group, P-valueof< 0.05 while rest of the symptoms were statistically same with a p-value of > 0.05.
Conclusion: This study concluded that the symptomatic relief of GERD after 2 weeks of therapy with Esomeprazole and Dexlansoprazole was the same except for dysphagia.
Keywords: Dexlansoprazole, Esomeprazole,Gastroesophageal reflux disease.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
